4
Changes in Ownership
Amylyx Pharmaceuticals, Inc. Filed Acc 0000899243-23-011461
Chief Medical Officer sold 49,579 shares at an average $30.54 ($1,513,942)
- Chief Medical Officer acquired 49,579 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Yeramian Patrick D Chief Medical Officer | 2023-04-17 | Option exercise 10b5-1 | +44,861 | $0.37 | $16,599 | 253,278 | D: show line 1 in the form |
| Yeramian Patrick D Chief Medical Officer | 2023-04-17 | Option exercise 10b5-1 | +4,718 | $6.88 | $32,460 | 257,996 | D: show line 2 in the form |
| Yeramian Patrick D Chief Medical Officer | 2023-04-17 | Sale 10b5-1 | −49,279 | $30.53 | $1,504,660 | 208,717 | D: show line 3 in the form |
| Yeramian Patrick D Chief Medical Officer | 2023-04-17 | Sale 10b5-1 | −300 | $30.94 | $9,282 | 208,417 | D: show line 4 in the form |
| Open-market sales · 49,579 sh · avg $30.54 · $1,513,942 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Yeramian Patrick D Chief Medical Officer | 2023-04-17 | Option exercise · Stock Option (right to buy) 10b5-1 | −44,861 | 17,605 | D: show line 5 in the form | ||
| Yeramian Patrick D Chief Medical Officer | 2023-04-17 | Option exercise · Stock Option (right to buy) 10b5-1 | −4,718 | 43,534 | D: show line 6 in the form |
Loading xslF345X04/doc4.xml…